An open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis

The primary endpoints of the trial are to determine the pharmacokinetic parameters for oral voriconazole and to determine if voriconazole serum levels >1.0mg L-1 are achieved in adult patients with cystic fibrosis using a standard oral dosing regimen.